Arrivent Biopharma, Common Stock EBITDA
| AVBP Stock | 27.45 0.86 3.23% |
ArriVent BioPharma, Common fundamentals help investors to digest information that contributes to ArriVent BioPharma,'s financial success or failures. It also enables traders to predict the movement of ArriVent Stock. The fundamental analysis module provides a way to measure ArriVent BioPharma,'s intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ArriVent BioPharma, stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | -67.1 M | -70.5 M |
ArriVent | EBITDA |
ArriVent BioPharma, Common Company EBITDA Analysis
ArriVent BioPharma,'s EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current ArriVent BioPharma, EBITDA | (74.59 M) |
Most of ArriVent BioPharma,'s fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ArriVent BioPharma, Common is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
ArriVent EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for ArriVent BioPharma, is extremely important. It helps to project a fair market value of ArriVent Stock properly, considering its historical fundamentals such as EBITDA. Since ArriVent BioPharma,'s main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of ArriVent BioPharma,'s historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of ArriVent BioPharma,'s interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
ArriVent Ebitda
According to the company disclosure, ArriVent BioPharma, Common reported earnings before interest,tax, depreciation and amortization of (74.59 Million). This is 108.5% lower than that of the Biotechnology sector and 174.47% lower than that of the Health Care industry. The ebitda for all United States stocks is 101.91% higher than that of the company.
ArriVent EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ArriVent BioPharma,'s direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ArriVent BioPharma, could also be used in its relative valuation, which is a method of valuing ArriVent BioPharma, by comparing valuation metrics of similar companies.ArriVent BioPharma, is currently under evaluation in ebitda category among its peers.
ArriVent Fundamentals
| Return On Equity | -0.31 | ||||
| Return On Asset | -0.21 | ||||
| Current Valuation | 499.58 M | ||||
| Shares Outstanding | 33.59 M | ||||
| Shares Owned By Insiders | 13.64 % | ||||
| Shares Owned By Institutions | 64.80 % | ||||
| Number Of Shares Shorted | 3.54 M | ||||
| Price To Book | 2.69 X | ||||
| EBITDA | (74.59 M) | ||||
| Net Income | (69.33 M) | ||||
| Total Debt | 317 K | ||||
| Book Value Per Share | 8.85 X | ||||
| Cash Flow From Operations | (55.84 M) | ||||
| Short Ratio | 10.97 X | ||||
| Earnings Per Share | (2.24) X | ||||
| Target Price | 38.0 | ||||
| Number Of Employees | 40 | ||||
| Market Capitalization | 798 M | ||||
| Total Asset | 163.1 M | ||||
| Retained Earnings | (157.84 M) | ||||
| Working Capital | 148.34 M | ||||
| Net Asset | 163.1 M |
About ArriVent BioPharma, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ArriVent BioPharma, Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ArriVent BioPharma, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ArriVent BioPharma, Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with ArriVent BioPharma,
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ArriVent BioPharma, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ArriVent BioPharma, will appreciate offsetting losses from the drop in the long position's value.Moving against ArriVent Stock
| 0.71 | MTEM | Molecular Templates | PairCorr |
| 0.67 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.62 | TPST | Tempest Therapeutics | PairCorr |
| 0.6 | ME | 23Andme Holding | PairCorr |
| 0.57 | AGL | agilon health | PairCorr |
The ability to find closely correlated positions to ArriVent BioPharma, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ArriVent BioPharma, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ArriVent BioPharma, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ArriVent BioPharma, Common to buy it.
The correlation of ArriVent BioPharma, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ArriVent BioPharma, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ArriVent BioPharma, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ArriVent BioPharma, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for ArriVent Stock Analysis
When running ArriVent BioPharma,'s price analysis, check to measure ArriVent BioPharma,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ArriVent BioPharma, is operating at the current time. Most of ArriVent BioPharma,'s value examination focuses on studying past and present price action to predict the probability of ArriVent BioPharma,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ArriVent BioPharma,'s price. Additionally, you may evaluate how the addition of ArriVent BioPharma, to your portfolios can decrease your overall portfolio volatility.